Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Vivimed Labs Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹4.95
High
₹5.19
Price Summary
| Previous Close | ₹5.00 |
|---|---|
| Day's Range | ₹4.95 - ₹5.19 |
| Open | ₹4.95 |
| 52 Week Range | ₹04.93 - ₹29.40 |
| Volume | 8,992 |
| Market Cap | ₹0.00 |
| Previous Close | ₹5.18 |
|---|---|
| Day's Range | ₹4.91 - ₹5.18 |
| Open | ₹4.91 |
| 52 Week Range | ₹04.95 - ₹27.99 |
| Volume | 466 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 0.45 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -21.28 |
| P/E Ratio | 0.00 |
| Book Value(₹) | -0.17 |
| PAT Margin (%) | -27.49 |
| Face Value (₹) | 2.00 |
| ROCE(%) | -9.07 |
| Trade Value ( ₹ in Lacs) | 0.02 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -21.28 |
| P/E Ratio | 0.00 |
| Book Value(₹) | -0.17 |
| PAT Margin (%) | -27.49 |
| Face Value (₹) | 2.00 |
| ROCE(%) | -9.07 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 225.75 | 1036.04 |
| Expenses | N/A | N/A |
| PBT | -44.17 | -314.96 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -44.17 | -314.96 |
About Vivimed Labs Ltd.
| Founded | 1988 |
|---|---|
| Managing Director | Santosh Varalwar |
| NSE Symbol | VIVIMEDLAB |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,66,430.72 | 1,951.35 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,20,114.60 | 8,320.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,88,852.64 | 4,950.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,715.98 | 8,970.75 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,19,158.34 | 1,467.70 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,348.86 | 1,105.95 | 835.50 - 835.50 |
| Lupin Ltd. | 1,09,347.72 | 2,394.90 | 1,855.00 - 1,855.00 |
| Max Healthcare Institute Ltd. | 1,04,626.89 | 1,081.95 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,00,395.19 | 2,430.60 | 1,909.70 - 1,909.70 |
| Laurus Labs Ltd. | 99,201.32 | 1,842.55 | 810.05 - 810.05 |
No Records Found
Latest News
Aug
7
2026
Posted on Aug 7th 2026
Procter&Gamble Healt - Quaterly Results
The Revenue for the quarter ended June 2026 of Rs. 3637.10 millions grew by 7.37 % from Rs. 3387.40 millions.Net Profit recorded in the quarter ended June 2026 rise to 45.29% to Rs. 961.50 millions compared to R. 661.80 millions in corresponding previous quarter.Operating profit for the quarter ended June 2026 rose to 1034.80 millions as compared to 943.70 millions of corresponding quarter ended June 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 3637.10 | 3387.40 | 7.37 | 3637.10 | 3387.40 | 7.37 | 14079.70 | 0.00 | 0.00 |
| Other Income | 38.80 | 40.30 | -3.72 | 38.80 | 40.30 | -3.72 | 173.40 | 0.00 | 0.00 |
| PBIDT | 1034.80 | 943.70 | 9.65 | 1034.80 | 943.70 | 9.65 | 4740.00 | 0.00 | 0.00 |
| Interest | 1.40 | 1.20 | 16.67 | 1.40 | 1.20 | 16.67 | 5.50 | 0.00 | 0.00 |
| PBDT | 1351.40 | 942.50 | 43.38 | 1351.40 | 942.50 | 43.38 | 4734.50 | 0.00 | 0.00 |
| Depreciation | 60.20 | 54.40 | 10.66 | 60.20 | 54.40 | 10.66 | 235.90 | 0.00 | 0.00 |
| PBT | 1291.20 | 888.10 | 45.39 | 1291.20 | 888.10 | 45.39 | 4498.60 | 0.00 | 0.00 |
| TAX | 329.70 | 226.30 | 45.69 | 329.70 | 226.30 | 45.69 | 1229.50 | 0.00 | 0.00 |
| Deferred Tax | 19.40 | -3.10 | -725.81 | 19.40 | -3.10 | -725.81 | 44.60 | 0.00 | 0.00 |
| PAT | 961.50 | 661.80 | 45.29 | 961.50 | 661.80 | 45.29 | 3269.10 | 0.00 | 0.00 |
| Equity | 166.00 | 166.00 | 0.00 | 166.00 | 166.00 | 0.00 | 166.00 | 0.00 | 0.00 |
| PBIDTM(%) | 28.45 | 27.86 | 2.13 | 28.45 | 27.86 | 2.13 | 33.67 | 0.00 | 0.00 |
Read More
Aug
7
2026
Posted on Aug 7th 2026
Zim Laboratories - Quaterly Results
The sales moved up 30.27% to Rs. 930.48 millions for the June 2026 quarter as compared to Rs. 714.28 millions during the year-ago period.The Net Loss for the quarter ended June 2026 is Rs. -38.74 millions as compared to Net Loss of Rs. -16.93 millions of corresponding quarter ended June 2025Operating Profit reported a sharp decline to 33.93 millions from 58.10 millions in the corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 930.48 | 714.28 | 30.27 | 930.48 | 714.28 | 30.27 | 3704.82 | 3756.36 | -1.37 |
| Other Income | 9.86 | 14.76 | -33.20 | 9.86 | 14.76 | -33.20 | 113.90 | 56.21 | 102.63 |
| PBIDT | 33.93 | 58.10 | -41.60 | 33.93 | 58.10 | -41.60 | 409.70 | 488.90 | -16.20 |
| Interest | 36.43 | 33.04 | 10.26 | 36.43 | 33.04 | 10.26 | 132.02 | 113.86 | 15.95 |
| PBDT | -2.50 | 25.06 | -109.98 | -2.50 | 25.06 | -109.98 | 277.68 | 375.04 | -25.96 |
| Depreciation | 51.71 | 47.90 | 7.95 | 51.71 | 47.90 | 7.95 | 193.67 | 198.91 | -2.63 |
| PBT | -54.21 | -22.84 | 137.35 | -54.21 | -22.84 | 137.35 | 84.01 | 176.13 | -52.30 |
| TAX | -15.47 | -5.91 | 161.76 | -15.47 | -5.91 | 161.76 | 24.35 | 58.68 | -58.50 |
| Deferred Tax | -15.47 | -5.91 | 161.76 | -15.47 | -5.91 | 161.76 | -8.40 | 14.21 | -159.11 |
| PAT | -38.74 | -16.93 | 128.82 | -38.74 | -16.93 | 128.82 | 59.66 | 117.45 | -49.20 |
| Equity | 535.49 | 487.26 | 9.90 | 535.49 | 487.26 | 9.90 | 535.00 | 487.26 | 9.80 |
| PBIDTM(%) | 3.65 | 8.13 | -55.17 | 3.65 | 8.13 | -55.17 | 11.06 | 13.02 | -15.03 |
Read More
Aug
7
2026
Posted on Aug 7th 2026
Hikal - Quaterly Results
The Revenue for the quarter ended June 2026 of Rs. 4028.00 millions grew by 5.89 % from Rs. 3804.00 millions.The Net Loss for the quarter ended June 2026 is Rs. -75.00 millions as compared to Net Loss of Rs. -227.00 millions of corresponding quarter ended June 2025OP of the company witnessed a marginal growth to 387.00 millions from 258.00 millions in the same quarter last year.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 4028.00 | 3804.00 | 5.89 | 4028.00 | 3804.00 | 5.89 | 17126.00 | 18598.00 | -7.91 |
| Other Income | 18.00 | 10.00 | 80.00 | 18.00 | 10.00 | 80.00 | 123.00 | 50.00 | 146.00 |
| PBIDT | 387.00 | 258.00 | 50.00 | 387.00 | 258.00 | 50.00 | 2328.00 | 3335.00 | -30.19 |
| Interest | 149.00 | 171.00 | -12.87 | 149.00 | 171.00 | -12.87 | 621.00 | 752.00 | -17.42 |
| PBDT | 327.00 | 87.00 | 275.86 | 327.00 | 87.00 | 275.86 | 856.00 | 2583.00 | -66.86 |
| Depreciation | 427.00 | 394.00 | 8.38 | 427.00 | 394.00 | 8.38 | 1638.00 | 1344.00 | 21.88 |
| PBT | -100.00 | -307.00 | -67.43 | -100.00 | -307.00 | -67.43 | -782.00 | 1239.00 | -163.12 |
| TAX | -25.00 | -80.00 | -68.75 | -25.00 | -80.00 | -68.75 | -295.00 | 330.00 | -189.39 |
| Deferred Tax | -25.00 | -80.00 | -68.75 | -25.00 | -80.00 | -68.75 | -275.00 | 30.00 | -1016.67 |
| PAT | -75.00 | -227.00 | -66.96 | -75.00 | -227.00 | -66.96 | -487.00 | 909.00 | -153.58 |
| Equity | 247.00 | 247.00 | 0.00 | 247.00 | 247.00 | 0.00 | 247.00 | 247.00 | 0.00 |
| PBIDTM(%) | 9.61 | 6.78 | 41.66 | 9.61 | 6.78 | 41.66 | 13.59 | 17.93 | -24.19 |
Read More
Aug
7
2026
Posted on Aug 7th 2026
Suven Life Sciences - Quaterly Results
The topline for the June 2026 quarter moved up 91.00% to Rs. 35.66 millions as compared to Rs. 18.67 millions during the year-ago period.The Net Loss for the quarter ended June 2026 is Rs. -161.20 millions as compared to Net Loss of Rs. -147.78 millions of corresponding quarter ended June 2025 Operating profit Margin for the quarter ended June 2026 further decreased to -134.89% as compared to -134.10% of corresponding quarter ended June 2025
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 35.66 | 18.67 | 91.00 | 35.66 | 18.67 | 91.00 | 71.15 | 66.56 | 6.90 |
| Other Income | 75.24 | 5.89 | 1177.42 | 75.24 | 5.89 | 1177.42 | 139.10 | 107.26 | 29.68 |
| PBIDT | -134.89 | -134.10 | 0.59 | -134.89 | -134.10 | 0.59 | -490.91 | -412.11 | 19.12 |
| Interest | 4.76 | 0.00 | 0.00 | 4.76 | 0.00 | 0.00 | 1.58 | 0.47 | 236.17 |
| PBDT | -139.65 | -134.10 | 4.14 | -139.65 | -134.10 | 4.14 | -492.49 | -412.58 | 19.37 |
| Depreciation | 21.55 | 13.68 | 57.53 | 21.55 | 13.68 | 57.53 | 56.14 | 58.22 | -3.57 |
| PBT | -161.20 | -147.78 | 9.08 | -161.20 | -147.78 | 9.08 | -548.63 | -470.80 | 16.53 |
| TAX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | -161.20 | -147.78 | 9.08 | -161.20 | -147.78 | 9.08 | -548.63 | -470.80 | 16.53 |
| Equity | 263.99 | 218.07 | 21.06 | 263.99 | 218.07 | 21.06 | 263.72 | 218.07 | 20.93 |
| PBIDTM(%) | -378.27 | -718.26 | -47.34 | -378.27 | -718.26 | -47.34 | -689.96 | -619.16 | 11.44 |
Read More
Aug
7
2026
Posted on Aug 7th 2026
Emcure Pharma - Quaterly Results
The sales for the June 2026 quarter moved up 32.32% to Rs. 14509.31 millions as compared to Rs. 10965.73 millions during the corresponding quarter last year.Net profit surges 62.97% to Rs. 2001.08 millions from Rs. 1227.89 millions in the quarter ended June 2026.The company reported a good operating profit of 3646.15 millions compared to 2495.24 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 14509.31 | 10965.73 | 32.32 | 14509.31 | 10965.73 | 32.32 | 52431.88 | 43819.24 | 19.65 |
| Other Income | 250.32 | 215.24 | 16.30 | 250.32 | 215.24 | 16.30 | 2095.16 | 1188.07 | 76.35 |
| PBIDT | 3646.15 | 2495.24 | 46.12 | 3646.15 | 2495.24 | 46.12 | 13342.66 | 7656.44 | 74.27 |
| Interest | 327.76 | 205.38 | 59.59 | 327.76 | 205.38 | 59.59 | 1182.71 | 1129.62 | 4.70 |
| PBDT | 3318.39 | 2254.86 | 47.17 | 3318.39 | 2254.86 | 47.17 | 11909.24 | 6526.82 | 82.47 |
| Depreciation | 631.66 | 598.17 | 5.60 | 631.66 | 598.17 | 5.60 | 2467.33 | 2249.72 | 9.67 |
| PBT | 2686.73 | 1656.69 | 62.17 | 2686.73 | 1656.69 | 62.17 | 9441.91 | 4277.10 | 120.75 |
| TAX | 685.65 | 428.80 | 59.90 | 685.65 | 428.80 | 59.90 | 2112.32 | 1105.82 | 91.02 |
| Deferred Tax | -17.82 | -11.23 | 58.68 | -17.82 | -11.23 | 58.68 | -225.09 | -21.25 | 959.25 |
| PAT | 2001.08 | 1227.89 | 62.97 | 2001.08 | 1227.89 | 62.97 | 7329.59 | 3171.28 | 131.12 |
| Equity | 1896.80 | 1895.08 | 0.09 | 1896.80 | 1895.08 | 0.09 | 1895.90 | 1894.83 | 0.06 |
| PBIDTM(%) | 25.13 | 22.75 | 10.44 | 25.13 | 22.75 | 10.44 | 25.45 | 17.47 | 45.64 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Vivimed Labs Ltd. is ₹5.00 as of 2026-08-07.
The market capitalisation of Vivimed Labs Ltd. is ₹41.79 as of 2026-08-06.
The 1-year return of Vivimed Labs Ltd. is % as of .
The P/E ratio of Vivimed Labs Ltd. is 0.00 as of 2026-08-07.
The 52-week high and low of Vivimed Labs Ltd. are ₹29.40 and ₹4.93, respectively, as of 2026-08-07.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
